Alport syndrome epidemiology and demographics

Revision as of 16:06, 31 October 2013 by Rim Halaby (talk | contribs) (→‎Epidemiology and Demographics)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Alport syndrome Microchapters


Patient Information


Historical Perspective



Differentiating Alport syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alport syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Alport syndrome epidemiology and demographics

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alport syndrome epidemiology and demographics

CDC on Alport syndrome epidemiology and demographics

Alport syndrome epidemiology and demographics in the news

Blogs on Alport syndrome epidemiology and demographics

Directions to Hospitals Treating Alport syndrome

Risk calculators and risk factors for Alport syndrome epidemiology and demographics

Epidemiology and Demographics

Alport’s syndrome or hereditary nephritis is considered one of the most common familial nephropathies. Its incidence is 1 in 50,000 – 1/100,000 live births in the United States.[1] Since the original description, male gender has been noted to be associated with worse severity, suggesting maternal transmittance. Onset of symptoms often starts during infancy in X-linked Alport’s syndrome; patients reach ESRD during adolescence.[1] Patients with autosomal recessive Alport’s syndrome sometimes progress less rapidly; although they may still progress to ESRD early, they may reach ESRD during adult life.[1]

Worldwide, Alport’s syndrome is not predominant in a specific race, ethnicity, or within a geographic distribution.[2][3][4] In the USA, however, Western states have a significantly higher rate of Alport’s syndrome and is up to two-fold more common than other regions within the USA.

Although a hereditary disorder, spontaneous mutations comprise approximately 15-20% of new cases of Alport’s syndrome.[5]


  1. 1.0 1.1 1.2 Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013). "Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy". J Am Soc Nephrol. 24 (3): 364–75. doi:10.1681/ASN.2012020148. PMID 23349312.
  2. Gehrs KM, Pollock SC, Zilkha G (1995). "Clinical features and pathogenesis of Alport retinopathy". Retina. 15 (4): 305–11. PMID 8545576.
  3. Yoshioka K, Hino S, Takemura T, Maki S, Wieslander J, Takekoshi Y; et al. (1994). "Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody". Am J Pathol. 144 (5): 986–96. PMC 1887361. PMID 8178947.
  4. Myers JC, Jones TA, Pohjolainen ER, Kadri AS, Goddard AD, Sheer D; et al. (1990). "Molecular cloning of alpha 5(IV) collagen and assignment of the gene to the region of the X chromosome containing the Alport syndrome locus". Am J Hum Genet. 46 (6): 1024–33. PMC 1683837. PMID 2339699.
  5. McCarthy PA, Maino DM (2000). "Alport syndrome: a review". Clin Eye Vis Care. 12 (3–4): 139–150. PMID 11137428.

Template:WH Template:WS